Latest Headlines

Latest Headlines

Zafgen's obesity drug hits the mark in orphan disease trial

Zafgen's in-development obesity treatment led to significant weight loss in patients with obesity triggered by a brain injury, meeting its goals and sending the biotech's shares up nearly 8%.

Zafgen's promising obesity drug comes through in another midstage trial

Zafgen charted a third major victory for its in-development obesity drug, spurring weight loss for patients who have endured brain injuries and stoking hopes for success in Phase III.

Zafgen, Ardelyx bank $156M in IPOs, recalling biotech's winter boom

The market for biotech IPOs has largely cooled since a first-quarter explosion brought in more than $2 billion, but drug developers Zafgen and Ardelyx managed to turn back the clock in their debuts, cashing out for a combined $156 million.

Zafgen tees up an $86M IPO for eye-catching obesity drug

Zafgen has been turning heads with some jaw-dropping results from its mid-stage studies for a promising new obesity drug. And now the biotech hopes to parlay its eye-catching, if risky, technology into an $86 million IPO.

Zafgen lands a $45M round for its obesity drug study

Today, Cambridge, MA-based Zafgen said that it is banking $45 million from a Series E round, adding a group of new investors that includes RA Capital Management, Brookside Capital, Venrock, Alta Partners, an undisclosed blue chip investor and a private investor.

Zafgen obesity drug scores heavyweight success in PhII trial

Promising results from early-stage work on Zafgen's weight drug beloranib clear a path to a Phase IIb trial that can fine-tune the dose while taking more time to gauge the long-term impact of its treatment on weight and set the right tone for ongoing talks with investors about a new financing round for the biotech.

Zafgen's obesity drug attracts a high-profile spotlight

Reuters did an in-depth feature on Zafgen's promising obesity therapy beloranib. The drug works by blocking the methionine aminopeptidase 2, or MetAP2, enzyme--which plays a role in the body's production and use of fatty acids.

Zafgen's obesity drug drives dramatic weight loss in PhII test

CHICAGO-- Zafgen has revealed some impressive weight-loss data from a midstage study of its experimental therapy beloranib, highlighting interim results after 12 weeks of treatment in 19 obese white women, according to the company.

UPDATED: Third Rock Ventures adds $516M fund to back new portfolio of biotechs

Third Rock Ventures has established its third biotech fund in 6 years, bringing in a haul of $516 million for one of the most active groups of early-stage biotech investors in the world. The new fund, which brings the total it's raised to a whopping $1.3 billion-plus, will be used to launch another 16 or so drug developers.

Biotech star Zafgen nabs $21M round to back dramatic weight-loss drug

Alta Partners has jumped into the venture syndicate, joining prolific biotech investor Third Rock and its high-profile colleagues at Atlas Venture, which are gambling that beloranib, which inhibits the MetAP2 enzyme, can set a whole new standard for weight-loss treatments.